CDK4 and neoplasm: Subsequent testing of this compound for inhibitory activity against a panel of 285 functional kinases revealed that ON108110 is a multi-kinase inhibitor, with highest inhibitory activity against CDK4/6 and CK2 (Table 2), two kinases intimately associated with growth, survival and anti-apoptotic phenotypes of human tumor cells.